As part of the foundation stone-laying ceremony for the new building designed to produce vaccines, Unither Amiens hosted Alain Gest, President of Amiens Metropole, Sophie Remont, Director of Expertise and Programs at Bpifrance, and Jean-Christophe Loric, Regional Councilor for Hauts-de-France.
Unither Pharmaceuticals President Eric Goupil reaffirmed the group’s commitment to making healthcare solutions that improve and simplify patients’ lives accessible to as many people as possible thanks to Euroject®, an innovation based on Blow-Fill-Seal (BFS) technology for the unitary injection of vaccines and biological products.
The 6,000m² extension to Laboratoire Unither in Amiens will house vaccines and, more generally, biological products requiring BSL I and II. The project began in 2023 and will be completed in 2025. Three filling lines will be installed, and two more will be added, resulting in the production of more than one billion doses a year. This project represents a total investment of €95m and has received a financial contribution from the French government as part of the Future Investment Program.
![](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2023/08/Picture1-2.jpg)